While current CDKN2A-targeted cancer therapeutic strategies are still under exploration [48], a sequential approach that induces senescence followed by the elimination of senescent cells, or optimized combinations of therapeutic strategies with senolytics and senostatics, may enhance anti-tumor efficacy [49,50]. The gene discussed is CDKN2A; the disease is cancer.